REMIT-DAPA study at PHRI
completed

The objective of the REMIT-SITA study was to determine if in patients with recently-diagnosed T2DM, a 12-week course of sitagliptin, metformin, basal insulin glargine and lifestyle approaches would achieve drug-free diabetes remission in a higher proportion of patients than standard diabetes therapy at 24 weeks (three months after the drugs are stopped).

Participants will be randomized to 2 treatment groups: (a) a 12-week course of treatment with sitagliptin, metformin, insulin glargine and lifestyle therapy, and (b) standard diabetes therapy, and followed for a total of 64 weeks.

The primary outcome in this trial was diabetes remission evaluated at 24 weeks.

Study Type

Interventional - Drug

Study Design

Multicentre, open-label RCT

NO. of Countries

1

NO. of Sites

6

NO. of Participants

102

Study Period

2016-2019

Sponsor

PHRI

Merck

Back To Top